Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis
Table 1
Clinical characteristics of the two groups studied at baseline.
Characteristics
Entire cohort
Propensity score-matched cohort
SMT (n = 412)
ALSS (n = 378)
value
SMT (n = 310)
ALSS (n = 310)
value
Age (y)
44.0 (10.6)
46.9 (11.4)
0.097
45.4 (11.1)
46.8 (11.3)
0.286
Sex, male
351 (85.2)
337 (86.0)
0.097
271 (87.4)
274 (84.6)
0.712
HBV-DNA (log copies/mL)
5.1 (1.6)
5.1 (2.0)
0.641
5.2 (1.1)
5.1 (1.9)
0.705
Alanine transaminase level (IU/L)
388.5 (277.4)
341.1 (326.5)
0.010
376.3 (239.8)
360.4 (300.1)
0.695
Total bilirubin level (mg/dl)
22.1 (7.4)
24.4 (7.0)
0.002
22.7 (7.4)
23.9 (7.0)
0.121
Serum albumin level (g/L)
33.1 (5.9)
32.1 (6.3)
0.027
33.1 (5.6)
31.9 (5.4)
0.149
Platelet count (×105/mm3) (SD)
107.3 (56.3)
103.8 (48.1)
0.015
105.3 (57.9)
104.7 (45.8)
0.893
White cell count (×109/L)
9.1 (21.3)
7.9 (3.3)
0.018
9.4 (24.1)
7.6 (4.0)
0.197
Serum creatinine level (mg/dl)
82.3 (44.3)
76.5 (30.6)
0.006
72.6 (23.7)
68.5 (25.5)
0.088
International normalized ratio
2.5 (0.9)
2.5 (0.6)
0.759
2.3 (0.8)
2.4 (0.9)
0.687
Serum sodium (mEq/L)
137.6 (4.5)
136.0 (4.1)
<0.001
135.7 (4.9)
136.4 (3.7)
0.181
Hepatic encephalopathy ≥ grade II
9.5% (39/412)
13.8% (52/378)
0.059
10.3% (32/310)
14.2% (44/378)
0.142
Cirrhosis
158 (38.3)
161 (42.6)
0.225
118 (38.1)
133 (42.9)
0.220
MELD score
25.9 (5.2)
24.8 (5.6)
0.721
25.1 (5.2)
24.9 (5.6)
0.594
COSSH-ACLF grade
0.091
0.985
ACLF grade 1
226 (54.9)
235 (62.2)
207 (66.8)
209 (67.4)
ACLF grade 2
174 (42.2)
131 (34.7)
94 (30.3)
92 (29.7)
ACLF grade 3
12 (2.9)
12 (3.2)
9 (2.9)
9 (2.9)
Nucleos(t)ide analogues
<0.001
<0.001
Lamivudine
205
167
155
131
Entecavir
207
182
155
157
Tenofovir
0
18
0
14
Telbivudine
0
11
0
8
Values are expressed as number and percentage or mean ± SD unless otherwise specified. SMT, standard medical therapy; ALSS, artificial liver support system; MELD, model for end-stage liver disease; COSSH-ACLF, Chinese Group on the Study of Severe Hepatitis B-ACLF.
